Future in management of food allergies – recent achievements

digital illustration antibodiesFood allergies are very common in children (6-8%) and sometimes they can even be life-threatening. Also, the quality of life of young patients and their families is severely affected. Currently, therapy of allergy is limited to avoidance of allergens and “rescue” pharmacological treatment. More and more doctors believe that the future is in active approach to the problem. Anticipatory testing, early introduction of potential food allergens, and active tolerance induction are the basis of the new model of treatment. Read full text »

Early introduction of peanut to the diet for infants prevents the development of peanut allergy.

digital illustration antibodiesClinical studies have reported that early introduction of peanuts to the diet for infants proved to be safe and it caused reductions in development of peanut allergy in 81%. The Studies concerned with infants who were in a group of high risk of developing allergy. The research was supported by the National Institute of Allergy and Infectious Diseases (NIAID), which is part of the National Institutes of Health, and were conducted by the Immune Tolerance Network (ITN). The results of the research appeared on the pages of the New England Journal of Medicine and were presented at the annual meeting of the American Academy of Allergy, Asthma and Immunology.

Read full text »

Chronic Fatigue Syndrome – new facts

Chronic fatigue syndrome (CFS) has been not only definitional problem, but also diagnostic and therapeutic one for medical world. Scientists from Center for Infection and Immunity and from Department of Epidemiology, Columbia University Mailman School of Public Health, New York in their latest report come closer to the solution. Read full text »

Ultra-rush sublingual immunotherapy – safe and clinically efficient treatment for allergic rhinitis

Sublingual immunotherapy (SLIT) due to its convenient administration and clinical efficiency has become popular treatment option for allergic diseases in Europe. Recently, the group of Indian scientists (Balaji R et al.) evaluated safety, tolerability and clinical efficacy of ultra-rush sublingual immunotherapy among patients suffering from allergic rhinitis (AR). The results of the study, which were published in “Allergologia et immunopatologia”, confirmed the thesis that this novel therapy might reduce symptoms of AR without risk of severe adverse effects. Ultra-rush sublingual immunotherapy with short period of treatment can have better compliance. Read full text »

Malaria – vaccine against menacing disease invented

For the first time in history scientists have developed a vaccine against malaria. It is the effect of 24 years of work which results were revealed at the end of 2011. The development of vaccine called RTS S has been ranked to 10 biggest developments of the previous year by the Science magazine. Read full text »

Systemic sclerosis – bortezomib – is it wonder drug?

A study published in the Thorax journal reports that anticancer drug – bortezomib may be effective in auto-immune disease therapy. This regards especially to illnesses linked with tissue fibrosis. Mouse model of systemic sclerosis has been assessed. Bortezomib successfully blocked the development of the disease in animals. Read full text »

Improved outcomes of kidney transplantation

A team of scientists of the Universitätsmedizin Berlin together with other 16 transplant centres in Germany and Switzerland has tested a new therapeutic immunosuppressive strategy, positively affecting the function of the kidneys after transplantation. The results of the investigation, which was a success, were published online in the journal The Lancet. Read full text »

Cursed mold

Exposure to mold during infancy increases the risk of asthma. Tendency to development of asthma is three times higher among children living in mold contaminated areas. More on this topic can be found in the August issue of Annals of Allergy, Asthma & Immunology, scientific journal of the American College of Allergy, Asthma and Immunology (ACAAI). Read full text »